Novartis
NEWS
To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.
Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association.
A study published in the Annals of Internal Medicine highlights some of the problems that drug shortages bring to the healthcare system, including a rise in prices. The research, as highlighted by Business Insider, examined the prices of 917 drugs that were in shortage between 2015 and 2016.
Swiss pharma giant Novartis could be on its way to securing regulatory approval for its secondary progressive multiple sclerosis (SPMS) treatment siponimod.
The use of multiple, potentially costly, drugs during combination therapy all contributes to the high costs in oncology. DO you know why does immunotherapy cost so much?
Boston Pharma went on a buying binge, licensing a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.
Immuno-oncology comes pretty close to being a miracle cure for certain types of cancer. But it’s not perfect, and a recently reported isolated case demonstrates that there are risks.
Technology has had a massive impact on basically every area of life. One very important part of medical research that technology has been having a noticeable impact on is clinical trials.
Janssen Biotech, a Johnson & Johnson company, informed Aduro Biotech that it was terminating its research and license deals related to Aduro’s Listeria treatment for cancers.
JOBS
IN THE PRESS